综述:TL1A抑制剂在炎症性肠病中的机制依据与临床证据
本文为叙述性综述,总结TL1A-DR3轴在炎症性肠病中连接免疫激活、上皮屏障功能障碍与纤维化的分子机制,并汇总TL1A抑制剂在克罗恩病和溃疡性结肠炎早期临床试验中实现临床/内镜缓解的证据,III期项目正在进行。
要点
- TL1A过表达在模型中驱动克罗恩病样回肠炎、屏障破坏和纤维化。
- TL1A抑制剂在早中重度IBD试验中显示临床/内镜缓解,III期进行中。
- TL1A-DR3整合黏膜免疫与基质损伤,靶向炎症-纤维化连续体。
核心结论
- TL1A-DR3轴整合黏膜免疫与基质损伤,TL1A抑制剂作为新类别有望突破IBD治疗天花板。
研究设计与样本
- 叙述性综述,综合克罗恩病和溃疡性结肠炎中TL1A/DR3的临床前、转化和临床文献。
主要发现
- TL1A过表达在模型中驱动克罗恩病样回肠炎、屏障破坏和纤维化,阻断可减轻炎症和重塑。
- TL1A抑制剂(如tulisokibart、duvakitug)在早中重度IBD试验中显示临床/内镜缓解,III期项目正在进行。
临床怎么用
- TL1A抑制剂可作为靶向炎症-纤维化连续体的新型治疗选择,目前处于早期至III期临床开发阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumour necrosis factor-like ligand 1A (TL1A) and its receptor DR3 form a pivotal signalling dyad linking immune activation, epithelial barrier dysfunction and fibrogenesis in inflammatory bowel diseases. (IBD). AIMS: This narrative review summarizes the molecular biology of the TL1A-DR3 axis, its roles in intestinal inflammation, fibrosis, and extraintestinal manifestations, and the emerging therapeutic landscape of TL1A inhibition in IBD. METHODS: Narrative synthesis of preclinical, translational, and clinical literature on TL1A/DR3 in Crohn's disease and ulcerative colitis. RESULTS: TL1A overexpression drives Crohn's-like ileitis, barrier disruption, and fibrosis in models; blockade attenuates both inflammation and remodelling. TL1A inhibitors show clinical/endoscopic remission in early-phase moderate-severe IBD trials (e.g., tulisokibart, duvakitug), with phase 3 programs ongoing. CONCLUSION: TL1A-DR3 integrates mucosal immunity with stromal injury, positioning inhibitors as a novel class to overcome IBD therapeutic ceilings by targeting the inflammation-fibrosis continuum.
引用
- Goyal MK, Srivastava H, Sehgal T, et al. Review Article: TL1A Inhibitors in IBD - Mechanistic Rationale and Clinical Evidence. Aliment Pharmacol Ther. 2026. PMID: 41941212. doi:10.1111/apt.70648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。